Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.64 |
| ▸ | ACACB | O00763 | 18/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881684 | 0.92 | AKR1C3 (0.73) | AKR1C3AKR1C2ACACBPTGS2 | |
| SCHEMBL456460 | 0.88 | ACACB (0.65) | AKR1C3AKR1C2ACACB | |
| SCHEMBL16214700 | 0.84 | ACACB (0.64) | ACACB | |
| SCHEMBL8372706 | 0.82 | AKR1C3 (0.59) | AKR1C3AKR1C2ACACBPTGS2 | |
| SCHEMBL16214701 | 0.81 | ACACB (0.57) | ACACB | |
| SCHEMBL27513384 | 0.80 | AKR1C3 (0.57) | AKR1C3AKR1C2ACACBPTGS2 | |
| SCHEMBL7403967 | 0.79 | GPR88 (0.59) | AKR1C3AKR1C2ACACBPTGS2 | |
| SCHEMBL14599721 | 0.79 | GPR88 (0.59) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL8403335 | 0.79 | GPR88 (0.59) | AKR1C3AKR1C2ACACBPTGS2 | |
| SCHEMBL16214698 | 0.78 | ACACB (0.60) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614054-B1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8877754-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2614054-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2012032014-A1 | ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214782-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | AKR1C3 1330/4885AKR1C2 1568/4885ACACB 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.